Workflow
巨子生物(02367):2025 半年报点评:业绩稳健增长,控费良好

Investment Rating - The investment rating for the company is "Buy" [6][18] Core Insights - The company reported a steady growth in revenue and net profit for the first half of 2025, with year-on-year increases of 23% and 20% respectively, indicating strong performance and effective cost control [2][10] - The sales expense ratio has decreased year-on-year, highlighting improved operational efficiency [10] - The company is focusing on the performance of key products and new launches, which are expected to drive future growth [10] Financial Summary - Total revenue for 2023 is projected at 3,524 million RMB, with a growth forecast to 5,539 million RMB in 2024, and reaching 10,402 million RMB by 2027, reflecting a compound annual growth rate (CAGR) of 22.4% [4][12] - Net profit is expected to grow from 1,452 million RMB in 2023 to 3,795 million RMB by 2027, with a CAGR of 23.4% [4][12] - The company maintains a high gross profit margin, projected at 81.7% for the first half of 2025, despite a slight year-on-year decrease [10] Revenue Breakdown - For the first half of 2025, revenue from various channels showed significant growth: DTC online direct sales increased by 13%, e-commerce platform direct sales surged by 134%, and offline direct sales rose by 12% [10] - The main brand, "可复美," launched upgraded products that performed well in the market, indicating strong brand momentum [10] Product Development - The company continues to innovate with new product launches, including an upgraded collagen stick and a new skincare series, which are expected to enhance market presence and meet consumer demands [10]